All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub were pleased to speak to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Tiziano Barbui provides an introduction to myeloproliferative neoplasms in relation to biology and treatment options.
Tiziano Barbui gives an in-depth overview of the biology and treatment landscape of myeloproliferative neoplasms (MPN). He discusses the types of neoplasms that constitute MPN and the identified phenotype that drives this disease. Additionally, he discusses the disease characteristics, risk factors and its evolutionary potential to cancer. Tiziano Barbui also talks about the current treatment guidelines in both the US and Europe such as the IPSET-thrombosis classification.
An introduction to MPN: biology and treatment options
Withdrawal of ruxolitinib increases risk of mortality in patients with myelofibrosis and COVID-19
Outcomes of coronavirus 2019 disease (COVID-19) in patients with MPN are still not fully understood but the need for evidence-based recommendations on...
COVID-19: Implications for patients with myeloproliferative neoplasms
Summary of two presentations at the Texas Virtual MPN Workshop (TMW) 2020: First Annual Workshop and Meeting. The first from MPN Hub Steering Committee member Tiziano Barbui, in...
Subscribe to get the best content related to MPN delivered to your inbox